Testing of Real-Time Diagnostic Platform (HPView) for the Detection of High-risk HPV Strains in Urine


About this study

The purpose of this study is to test whether our developed real-time HPV detection platform (HPView) performs at a comparable level to the clinical gold-standard.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Patients being tested for HPV 16 and/or HPV 18 for clinical diagnosis.

Exclusion Criteria:

  • Vulnerable patients or patients unable to provide informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Marina Walther-Antonio, Ph.D.

Open for enrollment

Contact information:

Maureen Lemens R.N.



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer